N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia

Abstract Background This study compares the performance of the soluble fms-like tyrosine kinase 1 to placental growth factor (sFlt-1/PlGF) ratio and the cardiac biomarker N-terminal pro-B type natriuretic peptide (NT-proBNP) in the prediction of adverse outcomes in women with suspicion of PE. Methods A retrospective cohort study was conducted on women admitted at triage with signs and/or symptoms of PE (n = 340). Serum levels of sFlt-1, PlGF and NT-proBNP were determined by an electrochemiluminescence immunoassay (Roche Diagnostics). The main outcomes were early- or late-onset PE and development of adverse outcome, defined as delivery within the first week since clinical presentation or fetal/early neonatal death. Results NT-proBNP concentrations (ng/L) were significantly increased in PE versus non-PE women, both at versus 34) and ≥ 34 weeks of gestation (101 versus 49) (p  Conclusion NT-proBNP and sFlt-1/PlGF ratio can be used to predict the development of an adverse outcome.